Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VGA039
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Star Therapeutics Receives FDA Fast Track Designation for VGA039 in VWD
Details : VGA039 is an investigational monoclonal antibody that targets Protein S to restore balance in blood clotting. It is being evaluated for the treatment of von willebrand disease.
Product Name : VGA039
Product Type : Antibody
Upfront Cash : Inapplicable
January 06, 2025
Lead Product(s) : VGA039
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VGA039
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Sofinnova Investments
Deal Size : $90.0 million
Deal Type : Series C Financing
Details : The net proceeds from the financing will support clinical advancement of VGA039, a first-in-class antibody currently being evaluated in a Phase 1a/1b study for von Willebrand disease.
Product Name : VGA039
Product Type : Large molecule
Upfront Cash : Undisclosed
September 05, 2023
Lead Product(s) : VGA039
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Sofinnova Investments
Deal Size : $90.0 million
Deal Type : Series C Financing
Reset All
